9 September 2020

Sydney, Australia

## Nyrada Investor Webinar

**Sydney, 9 September 2020**: Nyrada Inc (ASX: NYR) is pleased to announce its participation in the ShareCafé Small Cap "Hidden Gems" webinar series to be held on Friday 11 September 2020 from 12:30pm AEST.

Nyrada CEO James Bonnar will provide an overview of the Company's lead programs and recent progress. The webinar event is free to attend.

To register for the event, please follow the link: <u>https://us02web.zoom.us/webinar/register/WN\_xgg5pzuDQtmC60Y0M6Bs2A</u>.

A replay the webinar will be made available following the event via the Company's website at <u>www.nyrada.com</u>.

## About Nyrada Inc

Nyrada is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular, neurological, and inflammatory/autoimmune diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, USA, and the liability of its stockholders is limited.

-ENDS-

Authorised by Mr John Moore, Non-Executive Chairman, on behalf of the Board.

www.nyrada.com

Investor & Corporate Enquiries: Prue Kelly T: 0459 022 445 E: info@nyrada.com **Company Secretary:** David Franks T: 02 8072 1400 E: David.Franks@automicgroup.com.au

Media Enquiries: Catherine Strong Citadel-MAGNUS T: 02 8234 0111 E: cstrong@citadelmagnus.com